Key Takeaways FactSet posted Q4 EPS of $4.05, missing estimates but rising 8.3% year over year.Revenues were $596.9M, up 6.2% y/y, with 4.5% organic growth.ASV plus professional services hit $2.4B, increasing 5.7% from last year.FactSet (FDS) has reported mixed results for the fourth quarter fiscal 2025, wherein earnings missed the Zacks Consensus Estimate but revenues surpassed the same.FDS’s earnings per share of $4.05 missed the consensus mark by 2.4% but increased 8.3% from the year-ago quarter. Revenue ...

Key Takeaways Rigel stock has jumped 76.7% in three months, fueled by strong momentum for Tavalisse.Tavalisse made up over 65% of net product sales in Q2 2025, the firm's best quarter yet.Rigel raised 2025 revenue guidance to $270-$280M, led by Tavalisse, Rezlidhia and Gavreto.Shares of Rigel Pharmaceuticals (RIGL) have rallied 76.7% in the past three months. This stock price rally can be attributed to growing investor confidence regarding the strong growth of the company’s lead drug, Tavalisse (fostamatini ...

Core Viewpoint - The FTC has accused Live Nation and Ticketmaster of violating the FTC Act and the Better Online Ticket Sales Act, highlighting concerns over deceptive practices and the use of automated bots in ticket sales [1] Group 1: Legal Allegations - The FTC claims that Live Nation and Ticketmaster engaged in deceptive practices in the marketplace, which is prohibited under the FTC Act [1] - The companies are also accused of violating the Better Online Ticket Sales Act, a law aimed at preventing the use of automated bots for ticket purchases and reselling at inflated prices [1]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Shares of the secondary mortgage market giant have more than tripled this year amid growing optimism that the Trump administration would address long-standing questions surrounding the company’s government conservatorship.Fannie Mae has been under federal conservatorship since 2008. Both Fannie Mae and Freddie Mac needed a government bailout in 2008 after the housing bubble burst, as they were exposed to risky loans and securities that included subprime mortgages. The companies suffered billions in losses b ...

Intel TodayINTCIntel$32.00 +7.10 (+28.50%) 52-Week Range$17.67▼$32.38Price Target$22.20Add to WatchlistAfter the start of a rally in August that captured significant investor attention, shares of Intel Corporation NASDAQ: INTC have entered a period of consolidation, establishing a new and higher base in the $25 to $26 range. This sideways trading, however, follows a period of positive fundamental development. While the stock chart has been relatively quiet, the company has executed on a series of distinct ...

Key Takeaways Coherent posted 16.4% top-line growth on AI-related Datacom transceiver demand.COHR's non-GAAP gross margin rose 290 bps to 38.1% in the June quarter.COHR's EBITDA margin of 24% beats industry and rivals despite lower research and development spend.Coherent Corp. (COHR) recorded 16.4% year-over-year growth in its top line during the June quarter, fueled by its AI-related Datacom transceiver business. Backed by research and development (R&D) prowess, COHR’s 800G transceiver, an important factor ...

Core Insights - Eli Lilly's orforglipron demonstrated superior efficacy in reducing A1C and body weight compared to Novo Nordisk's Rybelsus in a late-stage study for type II diabetes patients [1][2][9] Study Results - The 52-week phase III ACHIEVE-3 study showed orforglipron (12 mg and 36 mg) achieved a reduction in A1C by 1.9% and 2.2%, respectively, compared to Rybelsus's 1.1% and 1.4% [2][9] - 37.1% of patients on the highest dose of orforglipron achieved A1C <5.7% at week 52, versus 12.5% for Rybelsus [3] - Weight loss was significantly greater with orforglipron, with patients losing an average of 14.6 lbs (6.7%) on 12 mg and 19.7 lbs (9.2%) on 36 mg, compared to Rybelsus's 7.9 lbs (3.7%) and 11 lbs (5.3%) [3] Additional Benefits - Orforglipron also showed improvements in cardiovascular risk factors, including non-HDL cholesterol, systolic blood pressure, and triglycerides, indicating its potential as a foundational oral therapy for diabetes [4] Safety Profile - The treatment was well-tolerated with an acceptable safety profile, primarily involving mild to moderate gastrointestinal adverse events [5] Ongoing Research - Eli Lilly is conducting seven late-stage studies for orforglipron in T2D and obesity, with previous studies showing consistent positive results in A1C reduction and weight loss [6] Market Position - GLP-1 therapies like orforglipron offer a differentiated mechanism of action, providing a convenient oral alternative to injectable therapies, with regulatory applications planned for later this year [7] Competitive Landscape - Novo Nordisk's Rybelsus recently received EU approval for cardiovascular benefits, enhancing its market position as the only oral GLP-1 agonist with proven heart benefits [8] Stock Performance and Valuation - Eli Lilly's stock has underperformed the S&P 500 but outperformed the sector, with a current price/earnings ratio of 26.5, higher than the industry average of 14.78 [11][14] - Earnings estimates for 2025 and 2026 have improved, indicating positive market sentiment [16]

Core Viewpoint - Germany's economy ministry is considering the possibility of merging all or parts of the former Gazprom unit SEFE with the financially supported company Uniper [1] Group 1 - The German economy ministry oversees the ownership of SEFE, which was previously a unit of Gazprom [1] - There are discussions among officials regarding the potential combination of SEFE with Uniper, which has received a bailout [1]

To gain an edge, this is what you need to know today.U.S. Vs. ChinaPlease click here for an enlarged chart of Intel Corp INTC.Note the following:This article is about the big picture, not an individual stock.  The chart of INTC stock is being used to illustrate the point.The chart shows INTC stock has jumped about 30% on the news that NVIDIA Corp NVDA will invest $5B in Intel and co-develop chips.The chart shows that INTC stock has broken out.The chart shows INTC stock is nearing zone 2 (resistance).RSI on ...